Vaccines, blood, antisera, toxins and cultures in   Singapore

Exports In 2022, Singapore exported $4.62B in Vaccines, blood, antisera, toxins and cultures, making it the 14th largest exporter of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 13th most exported product in Singapore. The main destination of Vaccines, blood, antisera, toxins and cultures exports from Singapore are: United States ($2.49B), Switzerland ($569M), Germany ($239M), Belgium ($235M), and South Korea ($232M).

The fastest growing export markets for Vaccines, blood, antisera, toxins and cultures of Singapore between 2021 and 2022 were South Korea ($115M), Switzerland ($109M), and Germany ($56.2M).

Imports In 2022, Singapore imported $2.01B in Vaccines, blood, antisera, toxins and cultures, becoming the 25th largest importer of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 27th most imported product in Singapore. Singapore imports Vaccines, blood, antisera, toxins and cultures primarily from: Spain ($673M), United States ($265M), Belgium ($180M), Sweden ($174M), and Switzerland ($127M).

The fastest growing import markets in Vaccines, blood, antisera, toxins and cultures for Singapore between 2021 and 2022 were Spain ($666M), United States ($38.6M), and United Kingdom ($26.2M).